Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
0.9569
-0.1031 (-9.73%)
Mar 31, 2025, 2:31 PM EDT - Market open
Alzamend Neuro Employees
As of April 30, 2024, Alzamend Neuro had 7 total employees, including 4 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$603,848
Market Cap
6.31M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ALZN News
- 6 days ago - Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital - GlobeNewsWire
- 13 days ago - Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital - GlobeNewsWire
- 20 days ago - Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital - GlobeNewsWire
- 27 days ago - Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital - GlobeNewsWire
- 4 weeks ago - Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital - GlobeNewsWire
- 8 months ago - Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details - Benzinga
- 8 months ago - Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder - Business Wire
- 11 months ago - Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program - Business Wire